T3 + T4 150mcg/tab 100 Tabletten by Genesis

Usage

1. Establish a morning administration time — take the tablet 30–60 minutes before the first meal to maximise GI absorption, as food (particularly calcium-rich foods) can reduce Levothyroxine uptake by up to 40 % according to pharmacokinetic data.
2. Begin at half the target dose (50–75 mcg) for the first 7–14 days to allow cardiovascular and CNS adaptation to rising T3 levels generated by peripheral T4 conversion.
3. If using a pill cutter to split the 150 mcg tablet, cut cleanly through the scored line to preserve dose accuracy — HPLC-uniform tablet composition means halves deliver approximately equal API content.
4. Track basal body temperature each morning before rising: a sustained rise of 0.3–0.5 °C above pre-cycle baseline confirms active thyroid axis engagement and successful T4-to-T3 conversion.
5. Separate Levothyroxine administration from any calcium, iron, or magnesium supplements by at least four hours, as these minerals form insoluble complexes with T4 in the GI tract and reduce bioavailability.
6. Run a post-cycle TSH and free T4 blood panel 4–6 weeks after completing the taper phase to confirm full hypothalamic–pituitary–thyroid (HPT) axis recovery before considering repeat use.

Warnings

Frequently asked questions

How does Levothyroxine (T4) actually increase basal metabolic rate at the cellular level?

Levothyroxine raises BMR after peripheral conversion to T3, which then upregulates mitochondrial oxidative phosphorylation, stimulates Na⁺/K⁺-ATPase pump activity (responsible for an estimated 20–40 % of resting energy expenditure), and accelerates substrate cycling. The net result is increased heat production and higher caloric turnover at rest — without requiring direct T3 administration.

What is the key functional difference between T4 (Levothyroxine) and T3 (Liothyronine) in terms of metabolism?

T4 is a pro-hormone that must be converted to T3 by deiodinase enzymes (DIO1, DIO2) in liver and muscle tissue before it can bind thyroid hormone receptors. T3 acts directly and rapidly, while T4 provides a sustained, tissue-regulated release of active hormone. This makes T4 supplementation more gradual in onset and offset compared to exogenous T3.

Why is the thyroid axis described as particularly sensitive to dose changes?

TSH suppression follows a log-linear relationship with free T4 serum concentration, meaning small absolute changes in circulating T4 trigger large relative changes in pituitary TSH output and endogenous thyroid gland activity. At a 150 mcg dose, a ±10 % potency deviation equals ±15 mcg — a margin equivalent to a full clinical adjustment step, which is why HPLC-confirmed tablet potency is critical.

Are the 150 mcg Genesis Levothyroxine tablets easy to split for lower starting doses?

The tablets are manufactured to uniform dimensions and consistent API distribution confirmed by HPLC batch testing, making them suitable for splitting with a pill cutter if a lower introductory dose is preferred. Starting at 50–75 mcg and titrating upward in 25–50 mcg increments over several weeks is the standard approach to minimize cardiovascular and CNS adaptation demands.

How are the Genesis T3 + T4 Levothyroxine 150 mcg tablets packaged and stored?

Tablets are packaged in a 100-count format designed for controlled dispensing and are best stored at room temperature (15–25 °C), away from direct light and moisture. Blister or sealed container packaging maintains tablet integrity over the shelf life stated on the batch label; avoid storing in humid environments such as bathrooms, as moisture can compromise tablet stability. (2) angle_used

Manufacturer

Genesis's approach to Levothyroxine sodium — at the 150 mcg concentration — is shaped by a specific challenge that distinguishes this compound from most other oral tablets in its portfolio: the therapeutic window is narrow and the clinical consequences of under-dose or over-dose manifest rapidly through measurable physiological endpoints, most visibly heart rate and body temperature. Rather than treating the 150 mcg declared strength as a nominal target, Genesis anchors it to a two-point analytical verification structure. The incoming Levothyroxine sodium API receives quantitative HPLC analysis against a certified primary reference standard, generating a batch-specific potency record that governs tablet compression input weights. A second, independent HPLC assay is then applied to finished tablets sampled from the packaged batch — confirming that the API content declared on the label is present in the unit that reaches the end user. LAL (Limulus Amebocyte Lysate) endotoxin screening at the raw material stage and ISO-classified, GMP-compliant production space complete the release architecture. Genesis's documented history across its oral ancillary and hormone tablet lines reflects a manufacturer that treats analytical sign-off as a release condition, not an optional quality layer — a posture that carries particular relevance for a thyroid compound where potency accuracy directly translates to axis-level physiological effect.